Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer

Aim: Carboplatin plus paclitaxel is a more costly chemotherapy regimen than cisplatin plus etoposide; however there have been reports of higher efficacy and less toxicity of this regimen. Thus, this study aimed to assess the cost-effectiveness of these two chemotherapy regimens in advanced non-small...

Full description

Saved in:
Bibliographic Details
Main Authors: Thongprasert S., Permsuwan U., Ruengorn C., Charoentum C., Chewaskulyong B.
Format: Article
Language:English
Published: 2014
Online Access:http://www.scopus.com/inward/record.url?eid=2-s2.0-83355175819&partnerID=40&md5=d442a1b1a609d7e2dc0410d388bf1123
http://www.ncbi.nlm.nih.gov/pubmed/22151987
http://cmuir.cmu.ac.th/handle/6653943832/4558
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
Language: English

Similar Items